TMS for Exposure Therapy Resistant OCD
Key facts
- Who runs it
- Amsterdam UMC, location VUmc
- Where
- Netherlands8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 250 people, planned
- Started
- 16 May 2022
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- repetitive transcranial magnetic stimulation (rTMS)
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- OCD as current primary diagnosis
- Age 18 and older
- Yale-Brown Obsessive-Compulsive Scale (YBOCS) score of 16 or higher
- Insufficient response to state-of-the art exposure therapy with response prevention (ERP) and/or drop-out from ERP due to extreme anxiety/avoidance
- The following comorbid disorders are allowed (as long as OCD is the current primary diagnosis): depression, other anxiety disorders, ADHD, tic/Tourette's disorder, eating disorders, personality disorders, autism spectrum disorder (when this does not dominate the clinical profile, i.e. is not main diagnosis)
- Commitment to actively undergo intensive exposure therapy (both supervised during ERP sessions, as well as unsupervised at home)
- Unmedicated (for at least 8 weeks) or stable dosage of psychotropic medication (for at least 8 weeks), involving serotonergic antidepressants (SSRI, SNRI, clomipramine). Other psychotropic medication that is allowed (provided dosage is stably established for at least 8 weeks): methylphenidate, mood stabilizers, antipsychotic drugs
- Ability to participate in frequent treatment sessions (4 days/week, for 5 (or 6, or 7) weeks) at one of the 5 sites nearest to their home and/or work
- Ability to participate in pre-treatment MRI session (for neuronavigation) at one of the 3 academic sites nearest to their home and/or work
- Capacity for providing informed consent
Who cannot take part
- Cochlear implant
- Previous rTMS treatment (for blinding reasons)
- The following comorbid disorders (current diagnosis) are not allowed: psychotic disorders, bipolar disorder, autism spectrum disorder (when this dominates the clinical profile, i.e. is diagnosed as main disorder), substance use disorder
- (History of) epilepsy
- OCD patients with hoarding as main symptom dimension
- Active suicidal thoughts and intent to act on it
- Chronic use of benzodiazepines is not allowed
- Pregnancy
- Extreme claustrophobia or metallic objects in or on the body, preventing from participation in MRI session
- Space-occupying lesion on MRI
This trial is currently available in Netherlands.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
TETRO is a multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months in 250 adult (18 years and older) OCD patients who show no/insufficient response to ERP, aiming to establish the cost-effectiveness of low frequency (1 Hz) rTMS to the pre-SMA (compared to sham rTMS to the pre-SMA) as adjuvant treatment to exposure with response prevention (ERP). The treatment consists of 4 times/week rTMS combined with ERP for at least 5 weeks (20 sessions), with optional extension phase of 1 or 2 weeks (maximum of 28 sessions in total).
The 2 groups in the trial
- real rTMSTreatment being tested
verum rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
Treatment: repetitive transcranial magnetic stimulation (rTMS)
- sham rTMSSham treatment, for comparison
sham rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
Treatment: repetitive transcranial magnetic stimulation (rTMS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Transcranial Magnetic Stimulation (TMS) for Patients With Exposure Therapy-resistant Obsessive-compulsive Disorder (OCD): TETRO - a Multicenter Randomized Controlled Trial
- Publications
- Record updated
- 4 March 2026